This is in line with the SMART and TEMPRANO studies, in which they have shown that starting ART early, regardless of CD4+ T cell count, can lead to improved health outcomes, including a decreased risk of opportunistic infections and, to some extent, a reduction in overall mortality [23,24]. The gene discussed is CD4; the disease is Opportunistic infection.